| NDC包装代码 | 产品NDC | 产品类型 | 商品名 | 通用名 | 剂型 | 给药途径 | 上市日期 | 结束日期 | 市场类别 | 申请号 | 标签持有者 | 活性成分 | 规格 | 包装描述 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 50419-390-01 | 50419-390 | HUMAN PRESCRIPTION DRUG | VITRAKVI | LAROTRECTINIB | CAPSULE | ORAL | 20190726 | N/A | NDA | NDA210861 | Bayer HealthCare Pharmaceuticals Inc. | LAROTRECTINIB | 25 mg/1 | 60 CAPSULE in 1 BOTTLE (50419-390-01) |
| 71777-391-01 | 71777-391 | HUMAN PRESCRIPTION DRUG | VITRAKVI | LAROTRECTINIB | CAPSULE | ORAL | 20181126 | N/A | NDA | NDA210861 | Loxo Oncology, Inc. | LAROTRECTINIB | 100 mg/1 | 60 CAPSULE in 1 BOTTLE (71777-391-01) |
| 50419-391-01 | 50419-391 | HUMAN PRESCRIPTION DRUG | VITRAKVI | LAROTRECTINIB | CAPSULE | ORAL | 20190726 | N/A | NDA | NDA210861 | Bayer HealthCare Pharmaceuticals Inc. | LAROTRECTINIB | 100 mg/1 | 60 CAPSULE in 1 BOTTLE (50419-391-01) |
| 71777-390-01 | 71777-390 | HUMAN PRESCRIPTION DRUG | VITRAKVI | LAROTRECTINIB | CAPSULE | ORAL | 20181126 | N/A | NDA | NDA210861 | Loxo Oncology, Inc. | LAROTRECTINIB | 25 mg/1 | 60 CAPSULE in 1 BOTTLE (71777-390-01) |